Item 2.01. Completion of Acquisition or Disposition of Assets.
On January 8, 2018, the registrant sold its entire holdings in CHA Biotech Co. Ltd, or CHA, consisting of 400,368 shares of CHA, or the CHA Shares, on the open market for aggregate net proceeds to the registrant of approximately $10.5 million, representing a net gain of $6.2 million. The CHA Shares were previously presented as Marketable Securities and classified in the registrants financial statement as available-for-sale in accordance with Accounting Standards Codification 320, Investments - Debt and Equity Securities. The registrant expects to recognize net financial income of $6.2 million from the sale of the CHA Shares in the registrants statement of operations for the nine months that will end on March 31 2018. For additional information regarding the registrants relationship with CHA, see Note 1.c of the notes to interim condensed consolidated financial statements contained in the registrants Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.
